Skip to main content
SpringerLink
Log in

Clinical Care for Individuals with Chronic Trypanosoma cruzi Infection: Decision-Making in the Midst of Uncertainty

  • Chapter
  • First Online:
Book cover Chagas Disease

Part of the book series: Birkhäuser Advances in Infectious Diseases ((BAID))

Abstract

This chapter discusses the reasoning behind clinical decisions for most individuals with chronic Trypanosoma cruzi infection (i.e., seropositive adults). It covers the goals and suggested strategies for diagnosis and treatment across the clinical spectrum of chronic Chagas cardiomyopathy (CCC), as the most relevant outcome for this population.

Uncertainty surrounds most clinical decisions for individuals at risk or with diagnosis of CCC. For such complex, neglected tropical disease, it has been very challenging to produce rigorous, longitudinal studies testing modern prognosis and therapy tools and recording a sufficient number of clinical events.

As a condition, being seropositive increases the risk of mortality at any clinical stage. Since the emergence of CCC is relatively infrequent, but substantial clinically, ruling out disease is critical upon serology diagnosis. We therefore propose a high-sensitivity initial approach, combining B-type natriuretic peptide with an electrocardiography (with a conventional ECG, adding a continuous monitoring for at least 1 h when negative). For those diagnosed with CCC, we propose to make use of Rassi’s (the only externally validated) scale for a risk-oriented clinical staging and disease monitoring.

As high-risk individuals, treatment should be considered always, paralleling complexity with CCC staging. Those with early or no disease will probably derive more benefit from trypanocidal therapy (TT) in order to clear parasitism and may not need another measure while CCC-free. A special, very important case is that of seropositive women in childbearing age, who should receive TT to prevent congenital transmission in future pregnancies. Adjuvant, proven treatment for heart failure from other origins is increasingly important for CCC patients and should be offered aggressively from early stages as an attempt to prevent its devastating complications and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pinto AY, Valente SA, Valente VC, Ferreira Junior AG, Coura JR. Acute phase of Chagas disease in the Brazilian Amazon region: study of 233 cases from Para, Amapa and Maranhao observed between 1988 and 2005. Rev Soc Bras Med Trop. 2008;41(6):602–14.

    Article  PubMed  Google Scholar 

  2. Noya BA, Diaz-Bello Z, Colmenares C, Ruiz-Guevara R, Mauriello L, Munoz-Calderon A, et al. Update on oral Chagas disease outbreaks in Venezuela: epidemiological, clinical and diagnostic approaches. Mem Inst Oswaldo Cruz. 2015;110(3):377–86.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Bern C, Martin DL, Gilman RH. Acute and congenital Chagas disease. Adv Parasitol. 2011;75:19–47.

    Article  PubMed  Google Scholar 

  4. Higuchi ML, Benvenuti LA, Martins RM, Metzger M. Pathophysiology of the heart in Chagas’ disease: current status and new developments. Cardiovasc Res. 2003;60(1):96–107.

    Article  CAS  Google Scholar 

  5. Validade do conceito de forma indeterminada de doença de Chagas. Rev Soc Bras Med Trop. 1985;18:46.

    Google Scholar 

  6. Dias JCP. The indeterminate form of human chronic Chagas’ disease: a clinical epidemological review. Rev Soc Bras Med Trop. 1989;22:147–56.

    Article  CAS  PubMed  Google Scholar 

  7. Pinto Dias JC. Natural history of Chagas disease. Arq Bras Cardiol. 1995;65(4):359–66.

    CAS  PubMed  Google Scholar 

  8. Bonney KM, Engman DM. Chagas heart disease pathogenesis: one mechanism or many? Curr Mol Med. 2008;8(6):510–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic Chagas heart disease. Circulation. 2007;115(9):1109–23.

    Article  PubMed  Google Scholar 

  10. Ferreira AW, de Avila SD. Laboratory diagnosis of Chagas’ heart disease. Sao Paulo Med J. 1995;113(2):767–71.

    Article  CAS  PubMed  Google Scholar 

  11. Umezawa ES, Silveira JF. Serological diagnosis of Chagas disease with purified and defined Trypanosoma cruzi antigens. Mem Inst Oswaldo Cruz. 1999;94(Suppl 1):285–8.

    Article  PubMed  Google Scholar 

  12. Ribeiro AL, Sabino EC, Marcolino MS, Salemi VM, Ianni BM, Fernandes F, et al. Electrocardiographic abnormalities in Trypanosoma cruzi seropositive and seronegative former blood donors. PLoS Negl Trop Dis. 2013;7(2):e2078.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Abras A, Munoz C, Ballart C, Berenguer P, Llovet T, Herrero M, et al. Towards a new strategy for diagnosis of congenital Trypanosoma cruzi infection. J Clin Microbiol. 2017;55(5):1396–407.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Buekens P, Cafferata ML, Alger J, Althabe F, Belizan JM, Bustamante N, et al. Congenital transmission of Trypanosoma cruzi in Argentina, Honduras, and Mexico: an observational prospective study. Am J Trop Med Hyg. 2018;98(2):478–85.

    Article  CAS  PubMed  Google Scholar 

  15. Marcus JE, Webber BJ, Cropper TL, Wilson MC, Yun HC. Diagnostic evaluation of military blood donors screening positive for Trypanosoma cruzi infection. MSMR. 2018;25(2):16–9.

    PubMed  Google Scholar 

  16. Massachusetts General Hospital. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32–1993. A native of El Salvador with tachycardia and syncope. N Engl J Med. 1993;329(7):488–96.

    Article  Google Scholar 

  17. Bimbi BJ, Unger P, Vandenbossche JL, Silance PG, Van LY. Chagas disease: don’t forget it in Latin American patients with heart block! Acta Cardiol. 2014;69(2):206–8.

    Article  PubMed  Google Scholar 

  18. Cucunuba ZM, Manne-Goehler JM, Diaz D, Nouvellet P, Bernal O, Marchiol A, et al. How universal is coverage and access to diagnosis and treatment for Chagas disease in Colombia? A health systems analysis. Soc Sci Med. 2017;175:187–98.

    Article  PubMed  Google Scholar 

  19. Manne JM, Snively CS, Ramsey JM, Salgado MO, Barnighausen T, Reich MR. Barriers to treatment access for Chagas disease in Mexico. PLoS Negl Trop Dis. 2013;7(10):e2488.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Sanchez DR, Traina MI, Hernandez S, Smer AM, Khamag H, Meymandi SK. Chagas disease awareness among Latin American immigrants living in Los Angeles, California. Am J Trop Med Hyg. 2014;91(5):915–9.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Meymandi SK, Hernandez S, Forsyth CJ. A community-based screening program for Chagas disease in the USA. Trends Parasitol. 2017;33(11):828–31.

    Article  PubMed  Google Scholar 

  22. Herrador Z, Rivas E, Gherasim A, Gomez-Barroso D, Garcia J, Benito A, et al. Using hospital discharge database to characterize Chagas disease evolution in Spain: there is a need for a systematic approach towards disease detection and control. PLoS Negl Trop Dis. 2015;9(4):e0003710.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Yamey G, Hotez P. Neglected tropical diseases. BMJ. 2007;335(7614):269–70.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Guyatt G, Montori V, Devereaux PJ, Schunemann H, Bhandari M. Patients at the centre: in our practice, and in our use of language. Evid Based Med. 2004;9(1):6.

    Article  Google Scholar 

  25. Cucunuba ZM, Okuwoga O, Basanez MG, Nouvellet P. Increased mortality attributed to Chagas disease: a systematic review and meta-analysis. Parasit Vectors. 2016;9:42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Capuani L, Bierrenbach AL, Pereira AA, Mendrone A Jr, Ferreira JE, Custer B, et al. Mortality among blood donors seropositive and seronegative for Chagas disease (1996–2000) in Sao Paulo, Brazil: a death certificate linkage study. PLoS Negl Trop Dis. 2017;11(5):e0005542.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ. Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas’ heart disease. Int J Cardiol. 2005;102(2):239–47.

    Article  PubMed  Google Scholar 

  28. Shen L, Ramires F, Martinez F, Bodanese LC, Echeverria LE, Gomez EA, et al. Contemporary characteristics and outcomes in Chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy. Circ Heart Fail. 2017;10(11):e004361.

    Article  PubMed  Google Scholar 

  29. Sabino EC, Ribeiro AL, Salemi VM, Di Lorenzo OC, Antunes AP, Menezes MM, et al. Ten-year incidence of Chagas cardiomyopathy among asymptomatic Trypanosoma cruzi-seropositive former blood donors. Circulation. 2013;127(10):1105–15.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J. Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy. Arq Bras Cardiol. 1985;45(4):249–56.

    CAS  PubMed  Google Scholar 

  31. Molina RB, Matsubara BB, Hueb JC, Zanati SG, Meira DA, Cassolato JL, et al. Dysautonomia and ventricular dysfunction in the indeterminate form of Chagas disease. Int J Cardiol. 2006;113(2):188–93.

    Article  PubMed  Google Scholar 

  32. Ribeiro AL, Moraes RS, Ribeiro JP, Ferlin EL, Torres RM, Oliveira E, et al. Parasympathetic dysautonomia precedes left ventricular systolic dysfunction in Chagas disease. Am Heart J. 2001;141(2):260–5.

    Article  CAS  PubMed  Google Scholar 

  33. Villar JC, Leon H, Morillo CA. Cardiovascular autonomic function testing in asymptomatic T. cruzi carriers: a sensitive method to identify subclinical Chagas’ disease. Int J Cardiol. 2004;93(2–3):189–95.

    Article  PubMed  Google Scholar 

  34. Simoes MV, Pintya AO, Bromberg-Marin G, Sarabanda AV, Antloga CM, Pazin-Filho A, et al. Relation of regional sympathetic denervation and myocardial perfusion disturbance to wall motion impairment in Chagas’ cardiomyopathy. Am J Cardiol. 2000;86(9):975–81.

    Article  CAS  PubMed  Google Scholar 

  35. de Almeida-Filho OC, Maciel BC, Schmidt A, Pazin-Filho A, Marin-Neto JA. Minor segmental dyssynergy reflects extensive myocardial damage and global left ventricle dysfunction in chronic Chagas disease. J Am Soc Echocardiogr. 2002;15(6):610–6.

    Article  PubMed  Google Scholar 

  36. Garcia-Alvarez A, Sitges M, Pinazo MJ, Regueiro-Cueva A, Posada E, Poyatos S, et al. Chagas cardiomyopathy: the potential of diastolic dysfunction and brain natriuretic peptide in the early identification of cardiac damage. PLoS Negl Trop Dis. 2010;21:4(9).

    Google Scholar 

  37. Pedrosa RC, Campos MC. Exercise testing and 24 hours Holter monitoring in the detection of complex ventricular arrhythmias in different stages of chronic Chagas’ heart disease. Rev Soc Bras Med Trop. 2004;37(5):376–83.

    Article  PubMed  Google Scholar 

  38. Villar JC. Challenges in identifying subclinical chronic chagasic cardiomyopathy in a Colombian urban population. PhD thesis dissertation. 2008. ISBN: 9780494360392 0494360399. OCLC Number: 434557667. https://www.researchgate.net/publication/254623471_Challenges_in_identifying_subclinical_chronic_chagasic_cardiomyopathy_in_a_Colombian_urban_population.

  39. Espinosa R, Carrasco HA, Belandria F, Fuenmayor AM, Molina C, Gonzalez R, et al. Life expectancy analysis in patients with Chagas’ disease: prognosis after one decade (1973–1983). Int J Cardiol. 1985;8(1):45–56.

    Article  CAS  PubMed  Google Scholar 

  40. Pereira JB, Willcox HP, Coura JR. Morbidade da doença de Chagas: III. Estudo longitudinal, de seis anos, em Virgem da Lapa, MG, Brasil. Mem Inst Oswaldo Cruz. 1985;80:63–71.

    Article  CAS  PubMed  Google Scholar 

  41. Acquatella H, Catalioti F, Gomez-Mancebo JR, Davalos V, Villalobos L. Long-term control of Chagas disease in Venezuela: effects on serologic findings, electrocardiographic abnormalities, and clinical outcome. Circulation. 1987;76(3):556–62.

    Article  CAS  PubMed  Google Scholar 

  42. Maguire JH, Hoff R, Sherlock I, Guimaraes AC, Sleigh AC, Ramos NB, et al. Cardiac morbidity and mortality due to Chagas’ disease: prospective electrocardiographic study of a Brazilian community. Circulation. 1987;75(6):1140–5.

    Article  CAS  PubMed  Google Scholar 

  43. Mota EA, Guimaraes AC, Santana OO, Sherlock I, Hoff R, Weller TH. A nine year prospective study of Chagas’ disease in a defined rural population in northeast Brazil. Am J Trop Med Hyg. 1990;42(5):429–40.

    Article  CAS  PubMed  Google Scholar 

  44. Maguire JH, Mott KE, Lehman JS, Hoff R, Muniz TM, Guimaraes AC, et al. Relationship of electrocardiographic abnormalities and seropositivity to Trypanosoma cruzi within a rural community in northeast Brazil. Am Heart J. 1983;105(2):287–94.

    Article  CAS  PubMed  Google Scholar 

  45. Hingorani P, Karnad DR, Rohekar P, Kerkar V, Lokhandwala YY, Kothari S. Arrhythmias seen in baseline 24-hour Holter ECG recordings in healthy normal volunteers during phase 1 clinical trials. J Clin Pharmacol. 2016;56(7):885–93.

    Article  CAS  PubMed  Google Scholar 

  46. von Rotz M, Aeschbacher S, Bossard M, Schoen T, Blum S, Schneider S, et al. Risk factors for premature ventricular contractions in young and healthy adults. Heart. 2017;103(9):702–7.

    Article  Google Scholar 

  47. Gontijo ED, Rocha MO, de OU T. Clinico-epidemiologic profile of Chagas disease patients attending an ambulatory referral center and proposal of a model of care for the Chagas patient under the perspective of a comprehensive health care. Rev Soc Bras Med Trop. 1996;29(2):101–8.

    Article  CAS  PubMed  Google Scholar 

  48. Davenport C, Cheng EY, Kwok YT, Lai AH, Wakabayashi T, Hyde C, et al. Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis. Br J Gen Pract. 2006;56(522):48–56.

    PubMed  PubMed Central  Google Scholar 

  49. Balion C, Santaguida PL, Hill S, Worster A, McQueen M, Oremus M, et al. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. Evid Rep Technol Assess (Full Rep). 2006;142:1–147.

    Google Scholar 

  50. Sanchez LV, Bautista DC, Corredor AF, Herrera VM, Martinez LX, Villar JC, et al. Temporal variation of Trypanosoma cruzi discrete typing units in asymptomatic Chagas disease patients. Microbes Infect. 2013;15(10–11):745–8.

    Article  PubMed  Google Scholar 

  51. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330(7492):625.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170(6):507–14.

    Article  CAS  PubMed  Google Scholar 

  53. McLellan J, Heneghan CJ, Perera R, Clements AM, Glasziou PP, Kearley KE, et al. B-type natriuretic peptide-guided treatment for heart failure. Cochrane Database Syst Rev. 2016;12:CD008966.

    PubMed  Google Scholar 

  54. Li P, Luo Y, Chen YM. B-Type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials. Heart Lung Circ. 2013;22(10):852–60.

    Article  PubMed  Google Scholar 

  55. Oliveira BM, Botoni FA, Ribeiro AL, Pinto AS, Reis AM, Nunes MC, et al. Correlation between BNP levels and Doppler echocardiographic parameters of left ventricle filling pressure in patients with Chagasic cardiomyopathy. Echocardiography. 2009;26(5):521–7.

    Article  PubMed  Google Scholar 

  56. Talvani A, Rocha MO, Cogan J, Maewal P, de Lemos J, Ribeiro AL, et al. Brain natriuretic peptide and left ventricular dysfunction in chagasic cardiomyopathy. Mem Inst Oswaldo Cruz. 2004;99(6):645–9.

    Article  CAS  PubMed  Google Scholar 

  57. Lima-Costa MF, Cesar CC, Peixoto SV, Ribeiro AL. Plasma B-type natriuretic peptide as a predictor of mortality in community-dwelling older adults with Chagas disease: 10-year follow-up of the Bambui Cohort Study of Aging. Am J Epidemiol. 2010;172(2):190–6.

    Article  PubMed  Google Scholar 

  58. Echeverria LE, Rojas LZ, Calvo LS, Roa ZM, Rueda-Ochoa OL, Morillo CA, et al. Profiles of cardiovascular biomarkers according to severity stages of Chagas cardiomyopathy. Int J Cardiol. 2017;227:577–82.

    Article  PubMed  Google Scholar 

  59. Clark EH, Marks MA, Gilman RH, Fernandez AB, Crawford TC, Samuels AM, et al. Circulating serum markers and QRS scar score in Chagas cardiomyopathy. Am J Trop Med Hyg. 2015;92(1):39–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Ribeiro AL, Teixeira MM, Reis AM, Talvani A, Perez AA, Barros MV, et al. Brain natriuretic peptide based strategy to detect left ventricular dysfunction in Chagas disease: a comparison with the conventional approach. Int J Cardiol. 2006;109(1):34–40.

    Article  PubMed  Google Scholar 

  61. Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263–82.

    Article  PubMed  Google Scholar 

  62. Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ. 2002;324(7336):539–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Laupacis A, Wells G, Richardson WS, Tugwell P. Users’ guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA. 1994;272(3):234–7.

    Article  CAS  PubMed  Google Scholar 

  64. Guida P, Mastro F, Scrascia G, Whitlock R, Paparella D. Performance of the European System for Cardiac Operative Risk Evaluation II: a meta-analysis of 22 studies involving 145,592 cardiac surgery procedures. J Thorac Cardiovasc Surg. 2014;148(6):3049–57.

    Article  PubMed  Google Scholar 

  65. Cardoso CS, Sabino EC, Oliveira CD, de Oliveira LC, Ferreira AM, Cunha-Neto E, et al. Longitudinal study of patients with chronic Chagas cardiomyopathy in Brazil (SaMi-Trop project): a cohort profile. BMJ Open. 2016;6(5):e011181.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Tassi EM, Continentino MA, Nascimento EM, Pereira BB, Pedrosa RC. Relationship between fibrosis and ventricular arrhythmias in Chagas heart disease without ventricular dysfunction. Arq Bras Cardiol. 2014;102(5):456–64.

    PubMed  PubMed Central  Google Scholar 

  67. Strauss DG, Cardoso S, Lima JA, Rochitte CE, Wu KC. ECG scar quantification correlates with cardiac magnetic resonance scar size and prognostic factors in Chagas’ disease. Heart. 2011;97(5):357–61.

    Article  PubMed  Google Scholar 

  68. Barbosa MM, Costa Rocha MO, Vidigal DF, Bicalho Carneiro RC, Araujo RD, Palma MC, et al. Early detection of left ventricular contractility abnormalities by two-dimensional speckle tracking strain in Chagas’ disease. Echocardiography. 2014;31(5):623–30.

    Article  PubMed  Google Scholar 

  69. Gomes VA, Alves GF, Hadlich M, Azevedo CF, Pereira IM, Santos CR, et al. Analysis of regional left ventricular strain in patients with Chagas disease and normal left ventricular systolic function. J Am Soc Echocardiogr. 2016;29(7):679–88.

    Article  PubMed  Google Scholar 

  70. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Acquatella H, Schiller NB, Puigbo JJ, Giordano H, Suarez JA, Casal H, et al. M-Mode and two-dimensional echocardiography in chronic Chages’ heart disease. A clinical and pathologic study. Circulation. 1980;62(4):787–99.

    Article  CAS  PubMed  Google Scholar 

  72. Nunes MCP, Badano LP, Marin-Neto JA, Edvardsen T, Fernandez-Golfin C, Bucciarelli-Ducci C, et al. Multimodality imaging evaluation of Chagas disease: an expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc Imaging. 2018;19(4):459–60.

    Article  PubMed  Google Scholar 

  73. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373–9.

    Article  CAS  PubMed  Google Scholar 

  74. Viotti R, Vigliano C, Lococo B, Petti M, Bertocchi G, Alvarez MG, et al. Clinical predictors of chronic chagasic myocarditis progression. Rev Esp Cardiol. 2005;58(9):1037–44.

    Article  PubMed  Google Scholar 

  75. Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and validation of a risk score for predicting death in Chagas’ heart disease. N Engl J Med. 2006;355(8):799–808.

    Article  CAS  PubMed  Google Scholar 

  76. Benchimol-Barbosa PR, Tura BR, Barbosa EC, Kantharia BK. Utility of a novel risk score for prediction of ventricular tachycardia and cardiac death in chronic Chagas disease – the SEARCH-RIO study. Braz J Med Biol Res. 2013;46(11):974–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Ribeiro AL, Rocha MO, Terranova P, Cesarano M, Nunes MD, Lombardi F. T-wave amplitude variability and the risk of death in Chagas disease. J Cardiovasc Electrophysiol. 2011;22(7):799–805.

    Article  PubMed  Google Scholar 

  78. de Souza AC, Salles G, Hasslocher-Moreno AM, de Sousa AS, Alvarenga Americano do Brasil PE, Saraiva RM, et al. Development of a risk score to predict sudden death in patients with Chaga’s heart disease. Int J Cardiol. 2015;187:700–4.

    Article  PubMed  Google Scholar 

  79. Ribeiro AL, Cavalvanti PS, Lombardi F, Nunes Mdo C, Barros MV, Rocha MO. Prognostic value of signal-averaged electrocardiogram in Chagas disease. J Cardiovasc Electrophysiol. 2008;19(5):502–9. https://doi.org/10.1111/j.1540-8167.2007.01088.x.

    Article  PubMed  Google Scholar 

  80. Silva RRD, Reis MS, Pereira BB, Nascimento EMD, Pedrosa RC. Additional value of anaerobic threshold in a general mortality prediction model in a urban patient cohort with Chagas cardiomyopathy. Rev Port Cardiol. 2017;36(12):927–34. https://doi.org/10.1016/j.repc.2017.06.012.

    Article  PubMed  Google Scholar 

  81. Sabino EC, Ribeiro AL, Lee TH, Oliveira CL, Carneiro-Proietti AB, Antunes AP, et al. Detection of Trypanosoma cruzi DNA in blood by PCR is associated with Chagas cardiomyopathy and disease severity. Eur J Heart Fail. 2015;17(4):416–23.

    Article  CAS  PubMed  Google Scholar 

  82. Villar JC, Perez JG, Cortes OL, Riarte A, Pepper M, Marin-Neto JA, et al. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev. 2014;5:CD003463.

    Google Scholar 

  83. Morillo CA, Marin-Neto JA, Avezum A, Sosa-Estani S, Rassi A Jr, Rosas F, et al. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med. 2015;373(14):1295–306.

    Article  CAS  PubMed  Google Scholar 

  84. Andrade AL, Martelli CM, Oliveira RM, Silva SA, Aires AI, Soussumi LM, et al. Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am J Trop Med Hyg. 2004;71(5):594–7.

    Article  CAS  PubMed  Google Scholar 

  85. Molina I, Prat J, Salvador F, Trevino B, Sulleiro E, Serre N, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;370(20):1899–908.

    Article  PubMed  CAS  Google Scholar 

  86. Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo MJ, Schijman A, et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis. 2018;18:419–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med. 2006;144(10):724–34.

    Article  CAS  PubMed  Google Scholar 

  88. Fragata-Filho AA, Franca FF, Fragata CS, Lourenco AM, Faccini CC, Costa CA. Evaluation of parasiticide treatment with benznidazol in the electrocardiographic, clinical, and serological evolution of Chagas disease. PLoS Negl Trop Dis. 2016;10(3):e0004508.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317(3):141–5.

    Article  CAS  PubMed  Google Scholar 

  90. Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med. 2011;364(5):476–80.

    Article  CAS  PubMed  Google Scholar 

  91. Sackett D. Why did I become a clinician-trialist? J R Soc Med. 2015;108(8):325–30.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet. 2001;357(9253):373–80.

    Article  CAS  PubMed  Google Scholar 

  93. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet. 2001;357(9254):455–62.

    Article  CAS  PubMed  Google Scholar 

  94. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288(7):872–81.

    Article  CAS  PubMed  Google Scholar 

  95. Walsh M, Srinathan SK, McAuley DF, Mrkobrada M, Levine O, Ribic C, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol. 2014;67(6):622–8.

    Article  PubMed  Google Scholar 

  96. Narayan VM, Gandhi S, Chrouser K, Evaniew N, Dahm P. The fragility of statistically significant findings from randomized controlled trials in the urologic literature. BJU Int. 2018;122(1):160–6.

    Article  PubMed  Google Scholar 

  97. Khan M, Evaniew N, Gichuru M, Habib A, Ayeni OR, Bedi A, et al. The fragility of statistically significant findings from randomized trials in sports surgery: a systematic survey. Am J Sports Med. 2017;45(9):2164–70.

    Article  PubMed  Google Scholar 

  98. Evaniew N, Files C, Smith C, Bhandari M, Ghert M, Walsh M, et al. The fragility of statistically significant findings from randomized trials in spine surgery: a systematic survey. Spine J. 2015;15(10):2188–97.

    Article  PubMed  Google Scholar 

  99. Durham J, Mackey WC. Perioperative beta-blockade in noncardiac surgery: a cautionary tale of over-reliance on small randomized prospective trials. Clin Ther. 2016;38(10):2302–16.

    Article  PubMed  Google Scholar 

  100. Yusuf S, Teo K, Woods K. Intravenous magnesium in acute myocardial infarction. An effective, safe, simple, and inexpensive intervention. Circulation. 1993;87(6):2043–6.

    Article  CAS  PubMed  Google Scholar 

  101. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;345(8951):669–85.

    Article  Google Scholar 

  102. Catalioti F, Acquatella H. Mortality comparison of 5 years follow up in subjects with chronic Chagas disease with and without benznidazol treatment [Comparación de mortalidad durante seguimiento por 5 años en sujetos con enfermedad de Chagas crónica con y sin tratamiento de benznidazol]. Rev Biol Trop. 1998;27(Suppl):29–31.

    Google Scholar 

  103. Silveira CAN. Avaliação a longo prazo do tratamento específico da doença de chagas [PhD thesis]. Distrito Federal, Brazil: Faculdade de Medicina, Universidade de Brasília, 2000:p. 123.

    Google Scholar 

  104. Fabbro de Suasnábar D, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo. 2000;42(2):99–109.

    Article  PubMed  Google Scholar 

  105. Lauria-Pires L, Braga M, Vexenat A, Nitz N, Simões-Barbosa A, Tinoco D, et al. Progressive chronic chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg. 2000;63(3, 4):111–8.

    Article  CAS  PubMed  Google Scholar 

  106. Gallerano R, Sosa R. Intervention study on the natural evolution of Chagas disease: evaluation of specific antiparasitic treatment [Estudio de intervencion en la evolucion natural de la enfermedad de Chagas: evaluacion del tratamiento antiparasitario especifico]. Rev Fac Cien Med Univ Nac Cordoba. 2000;57(2):135–62.

    CAS  PubMed  Google Scholar 

  107. Hess EP, Hollander JE, Schaffer JT, Kline JA, Torres CA, Diercks DB, et al. Shared decision making in patients with low risk chest pain: prospective randomized pragmatic trial. BMJ. 2016;355:i6165.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Branda ME, Leblanc A, Shah ND, Tiedje K, Ruud K, Van HH, et al. Shared decision making for patients with type 2 diabetes: a randomized trial in primary care. BMC Health Serv Res. 2013;13:301.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Alvarez MG, Vigliano C, Lococo B, Bertocchi G, Viotti R. Prevention of congenital Chagas disease by Benznidazole treatment in reproductive-age women. An observational study. Acta Trop. 2017;174:149–52.

    Article  CAS  PubMed  Google Scholar 

  110. Murcia L, Simon M, Carrilero B, Roig M, Segovia M. Treatment of infected women of childbearing age prevents congenital Trypanosoma cruzi infection by eliminating the parasitemia detected by PCR. J Infect Dis. 2017;215(9):1452–8.

    Article  CAS  PubMed  Google Scholar 

  111. Moscatelli G, Moroni S, Garcia-Bournissen F, Ballering G, Bisio M, Freilij H, et al. Prevention of congenital Chagas through treatment of girls and women of childbearing age. Mem Inst Oswaldo Cruz. 2015;110(4):507–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Fabbro DL, Danesi E, Olivera V, Codebo MO, Denner S, Heredia C, et al. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas. PLoS Negl Trop Dis. 2014;8(11):e3312.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Torrico F, Alonso-Vega C, Suarez E, Rodriguez P, Torrico MC, Dramaix M, et al. Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am J Trop Med Hyg. 2004;70(2):201–9.

    Article  PubMed  Google Scholar 

  114. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Department, Fundación Cardioinfantil-Instituto de Cardiología, Bogotá, Colombia

    Juan Carlos Villar & Pablo Andrés Bermudez

  2. Faculty of Health Sciences, Universidad Autónoma de Bucaramanga, Bucaramanga, Colombia

    Juan Carlos Villar

Authors
  1. Juan Carlos Villar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pablo Andrés Bermudez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juan Carlos Villar .

Editor information

Editors and Affiliations

  1. Servicio de Parasitología y Enfermedad de Chagas, Hospital de Niños “Ricardo Gutiérrez”, Buenos Aires, Argentina

    Jaime Marcelo Altcheh

  2. Servicio de Parasitología y Enfermedad de Chagas, Hospital de Niños “Ricardo Gutiérrez”, Buenos Aires, Argentina

    Hector Freilij

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Villar, J.C., Bermudez, P.A. (2019). Clinical Care for Individuals with Chronic Trypanosoma cruzi Infection: Decision-Making in the Midst of Uncertainty. In: Altcheh, J., Freilij, H. (eds) Chagas Disease. Birkhäuser Advances in Infectious Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-00054-7_10

Download citation

Publish with us

Policies and ethics

Search

Navigation